Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHERISH: ATM-AVI in Neonates and Infants With Gram-Negative Infections
NCT06462235Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of aztreonam, avibactam in Gram-negative bacterial infection, sponsored by Pfizer. Started Sep 2024; status: recruiting.
02
Drugs
aztreonamavibactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT06462235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462235.